Moclobemide versus imipramine in depressed out‐patients: a double‐blind multi‐centre study

@article{Rimn1993MoclobemideVI,
  title={Moclobemide versus imipramine in depressed out‐patients: a double‐blind multi‐centre study},
  author={Ranan Rim{\'o}n and J. J{\"a}{\"a}skel{\"a}inen and P Kaartinen and Anja Kalli and Edward Kilponen and Teuvo Koskinen and Heikki V. Nikkil{\"a} and V Pirttiper{\"a} and Jussi Sepp{\"a}l{\"a}},
  journal={International Clinical Psychopharmacology},
  year={1993},
  volume={7},
  pages={141–148}
}
One hundred and twenty seven patients with major depressive episode were included in a double-blind, four-week, prospective, randomized, multi-centre parallel-group trial comparing moclobemide and imipramine. The dose of moclobemide was 150–525 mg/day and that of imipramine 50–175 mg/day; the mean daily doses during the last week of treatment were 307 mg and 100 mg of moclobemide and imipramine, respectively. The decrease of the total scores of the Hamilton Depression Scale (HDRS) as well as… Expand
Moclobemide vs. imipramine in bipolar depression: a multicentre double‐blindclinical trial
TLDR
The data suggests that MCB is less likely than IMI to precipitate mania, and no differences in efficacy were detected between MCB and IMI in the treatment of bipolar depression. Expand
Treatment of Depression in Parkinson's with Moclobemide: A Pilot Open-label
TLDR
Though these preliminary results need to be replicated in a large controlled trial, it is suggested that moclobemide may be an effective alternative in the treatment of PD associated depression. Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Treatment of depression in Parkinson's disease with moclobemide: A pilot open-label study.
TLDR
Though these preliminary results need to be replicated in a large controlled trial, it is suggested that moclobemide may be an effective alternative in the treatment of PD associated depression. Expand
Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case
TLDR
An improvement of symptoms induced by a combination of moclobemide (MOC) and agomelatine (AG) treatment in a 48-year-old Caucasian woman with treatment-resistant major depressive disorder is presented. Expand
Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case
Treatment-resistant depression is a major depressive disorder that does not respond to adequate treatment of at least two antidepressants and is one of the major clinical challenges for cliniciansExpand
Moclobemide : An Update of its Pharmacological Properties and Therapeutic Use.
TLDR
Comparative studies have established that moclobemide is better tolerated at therapeutic dosages and has less toxicity in overdose than TCAs and nonselective, irreversible MAO inhibitors, and is also effective in patients with a primary diagnosis of social phobia. Expand
Health-related quality of life in patients with major depression who are treated with moclobemide.
A total of 651 depressed patients completed self-administered health-related quality-of-life (HRQOL) questionnaires during treatment with moclobemide in order to evaluate whether general andExpand
Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression
TLDR
A series of meta-analyses of studies of the two most widely researched RIMAs, moclobemide (MOC; Aurorex) and brofaromine (BRO) confirm that both BRO and MOC are as effective as the tricyclic antidepressants, and they are better tolerated. Expand
Hypo- and Hypersalivation Induced by Psychoactive Drugs
TLDR
It is important that the clinician is familiar with the effect of each class of drug on salivation, so that he/she can mitigate these by the judicious choice of drug and dosage schedule, and, if necessary, by providing symptomatic treatment for these distressing, and occasionally dangerous, adverse effects. Expand
...
1
2
...